Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells

Seo, JeongHyeon; Lee, Da Eun; Kim, Seong Mi; Kim, Eun-Jung; Kim, Jin-Kyung

doi:10.3390/biomedicines11051264

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signal transducer and activator of transcription 3 (STAT3) is another important transcription factor that regulates proliferation, survival, metastasis and invasion of ovarian cancer (Seo et al, 2023). From a diagnostic perspective, molecular profiling techniques can be employed to assess the activation status of the STAT3 pathway in ovarian cancer patients.…”

Section: Assessment Of Experimental Biomarkers As Future Theranostic ...mentioning

confidence: 99%

Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

Rajapaksha,

Khetan,

Johnson

et al. 2024

Front. Drug Deliv.

View full text Add to dashboard Cite

Ovarian cancers are a complex and heterogenic group of malignancies that are difficult to detect, diagnose and treat. Fortunately, considerable knowledge of ovarian cancer specific biomarkers has been generated, that is pertinent to the development of novel theranostic platforms by combining therapies and diagnostics. Genomic and proteomic data has been invaluable in providing critical biomolecular targets for ovarian cancer theranostic approaches. Exploitation of the wealth of biomarker research that has been conducted offers viable targets as beacons for ovarian cancer detection, diagnosis, and therapeutic targeting. These markers can be used in theranostics, a treatment strategy that combines therapy and diagnostics and is common in nuclear medicine, where radionuclides are used for both diagnosis and treatment. The development of theranostics has taken substantial focus in recent years in the battle against ovarian cancer. Yet to date only one theranostic technology has emerged in clinical practice. However, given the wealth of ovarian cancer biomarkers the field is poised to see the emergence of revolutionary disease treatment and monitoring outcomes through their incorporation into the development of theranostic strategies. The future of ovarian cancer treatment is set to enable precise diagnosis, targeted treatment, and vigilant monitoring. This review aims to assess the status of ovarian cancer diagnostic tools and biomarkers in practice, clinical development, or pre-clinical development, highlighting newly emerging theranostic applications.

show abstract

Section: Assessment Of Experimental Biomarkers As Future Theranostic ...mentioning

confidence: 99%

Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

Rajapaksha,

Khetan,

Johnson

et al. 2024

Front. Drug Deliv.

View full text Add to dashboard Cite

show abstract

“…Colon, breast, lung, and bladder [60][61][62][63][64][65][66][67][68][69][70][71] Broussochalcone A Broussonetia papyrifera (Moraceae) Renal [72] Isobavachalcone Psoralea corylifolia (Leguminosae) Breast [73,74] Pinostrobin Uvaria chamae (Annonaceae) Breast and prostate [75,76]…”

Section: Introductionmentioning

confidence: 99%

A Novel Tri-Hydroxy-Methylated Chalcone Isolated from Chromolaena tacotana with Anti-Cancer Potential Targeting Pro-Survival Proteins

Mendez-Callejas,

Piñeros-Avila,

Yosa-Reyes

et al. 2023

IJMS

View full text Add to dashboard Cite

Chromolaena tacotana (Klatt) R. M. King and H. Rob (Ch. tacotana) contains bioactive flavonoids that may have antioxidant and/or anti-cancer properties. This study investigated the potential anti-cancer properties of a newly identified chalcone isolated from the inflorescences of the plant Chromolaena tacotana (Klatt) R. M. King and H. Rob (Ch. tacotana). The chalcone structure was determined using HPLC/MS (QTOF), UV, and NMR spectroscopy. The compound cytotoxicity and selectivity were evaluated on prostate, cervical, and breast cancer cell lines using the MTT assay. Apoptosis and autophagy induction were assessed through flow cytometry by detecting annexin V/7-AAD, active Casp3/7, and LC3B proteins. These results were supported by Western blot analysis. Mitochondrial effects on membrane potential, as well as levels of pro- and anti-apoptotic proteins were analyzed using flow cytometry, fluorescent microscopy, and Western blot analysis specifically on a triple-negative breast cancer (TNBC) cell line. Furthermore, molecular docking (MD) and molecular dynamics (MD) simulations were performed to evaluate the interaction between the compounds and pro-survival proteins. The compound identified as 2′,3,4-trihydroxy-4′,6′-dimethoxy chalcone inhibited the cancer cell line proliferation and induced apoptosis and autophagy. MDA-MB-231, a TNBC cell line, exhibited the highest sensitivity to the compound with good selectivity. This activity was associated with the regulation of mitochondrial membrane potential, activation of the pro-apoptotic proteins, and reduction of anti-apoptotic proteins, thereby triggering the intrinsic apoptotic pathway. The chalcone consistently interacted with anti-apoptotic proteins, particularly the Bcl-2 protein, throughout the simulation period. However, there was a noticeable conformational shift observed with the negative autophagy regulator mTOR protein. Future studies should focus on the molecular mechanisms underlying the anti-cancer potential of the new chalcone and other flavonoids from Ch. tacotana, particularly against predominant cancer cell types.

show abstract

Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade

Han,

Wei,

Wang

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells

Cited by 4 publications

References 41 publications

Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

A Novel Tri-Hydroxy-Methylated Chalcone Isolated from Chromolaena tacotana with Anti-Cancer Potential Targeting Pro-Survival Proteins

Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade

Contact Info

Product

Resources

About